Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
US-2024376471-A1 · Nov 14, 2024 · US
US9434988B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9434988-B2 |
| Application number | US-201213429077-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 23, 2012 |
| Priority date | Apr 30, 2008 |
| Publication date | Sep 6, 2016 |
| Grant date | Sep 6, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides methods of cleaving a nucleic acid strand to initiate, assist, monitor or perform biological assays.
Opening claim text (preview).
What is claimed is: 1. A method of amplifying a target DNA sequence, the method comprising the steps of: (a) providing a reaction mixture at a starting temperature at or below 40° C. wherein the reaction mixture comprises: (i) a first oligonucleotide primer having a cleavage domain positioned 5′ of a blocking group, the blocking group linked at or near the end of the 3′-end of the oligonucleotide primer, wherein the blocking group prevents primer extension and/or PCR, (ii) a sample nucleic acid that may or may not have the target sequence, (iii) a cleaving enzyme, wherein the cleaving enzyme is an RNase H2 enzyme, (iv) a polymerase, and (v) optionally, a second oligonucleotide primer in reverse orientation to support PCR; (b) elevating the temperature of the reaction mixture to at or above 50° C. to increase the activity of the RNase H2 enzyme; (c) hybridizing the blocked oligonucleotide primer to the target DNA sequence to form a double-stranded substrate; (d) cleaving the hybridized oligonucleotide primer with the cleaving enzyme at a point within or adjacent to the cleavage domain to remove the blocking group from the oligonucleotide primer; and (e) extending the oligonucleotide primer with the polymerase, wherein the RNase H2 enzyme has, at the starting temperature, less than about 16% of the activity that the RNase H2 enzyme has at the elevated temperature in step (b). 2. The method of claim 1 wherein the cleavage domain is a single RNA residue. 3. The method of claim 1 wherein the amplification is performed in a PCR assay that is used to discriminate between variant alleles. 4. The method of claim 3 wherein the PCR assay is used to quantitate the abundance of the target nucleic acid sequence in the sample. 5. The method of claim 1 , wherein the starting temperature is at or below 37° C. 6. The method of claim 1 wherein the RNase H2 enzyme has, at the starting temperature, less than about 15% of the activity that the RNase H2 enzyme has at the elevated temperature in step (b). 7. The method of claim 1 wherein the RNase H2 enzyme has, at the starting temperature, less than about 5% of the activity that the RNase H2 enzyme has at the elevated temperature in step (b). 8. The method of claim 1 wherein the RNase H2 enzyme has, at the starting temperature, less than about 1% of the activity that the RNase H2 enzyme has at the elevated temperature in step (b). 9. The method of claim 1 wherein the RNase H2 enzyme is Pyrococcus abyssi RNase H2. 10. The method of claim 1 , wherein the RNase H2 enzyme is encoded by SEQ ID NO: 4. 11. The method of claim 1 , wherein the RNase H2 enzyme is reversibly inactivated either by chemical modification or by a blocking antibody.
Allele-specific amplification · CPC title
RNAse, e.g. RNAseH · CPC title
fluorescence · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.